Abstract We compared the enhancement effect between a newly synthesized tissue-specific contrast agent, [Gd-DOTA-FPbG], and a commercially available agent, [Gd(DOTA)] À , in a murine model of liver tumor using a clinical magnetic resonance imaging scanner. The colon cancer cell lines with and without b-glucuronidase (bG) expression were implanted into the liver of mice. Self-synthesized gadolinium-based magnetic resonance contrast agent, [Gd(DO-TA-FPbG)], was administered to measure enhancement on magnetic resonance images using a commercially available agent, [Gd(DOTA)] À , as control in a clinical 3.0 tesla (T) magnetic resonance scanner. In vivo fluorescence imaging and histopathology of the liver were also performed to compare and correlate with the magnetic resonance studies. The in vivo fluorescence imaging failed to depict a sufficiently intense signal for liver or liver tumor of mice without exposure of the liver following an incision on the abdominal wall. The tissuespecific magnetic resonance agent, [Gd(DOTA-FPbG)], caused significantly stronger enhancement in tumors expressing bG (CT26/mbG-eB7) than in tumors not expressing bG (CT26) (p < 0.05). In the magnetic resonance imaging studies using control agent [Gd(DOTA)] À , the tumors with and without bG expression depicted no significant difference in enhancement on the T1-weighted images. The [Gd(DOTA-FPbG)] also provided significantly more contrast uptake in the CT26/mbG-eB7 tumor than in the normal liver parenchyma, whereas the
a murine model of liver tumor using a clinical magnetic resonance imaging scanner. The colon cancer cell lines with and without b-glucuronidase (bG) expression were implanted into the liver of mice. Self-synthesized gadolinium-based magnetic resonance contrast agent, [Gd(DO-TA-FPbG)], was administered to measure enhancement on magnetic resonance images using a commercially available agent, [Gd(DOTA)] À , as control in a clinical 3.0 tesla (T) magnetic resonance scanner. In vivo fluorescence imaging and histopathology of the liver were also performed to compare and correlate with the magnetic resonance studies. The in vivo fluorescence imaging failed to depict a sufficiently intense signal for liver or liver tumor of mice without exposure of the liver following an incision on the abdominal wall. The tissuespecific magnetic resonance agent, [Gd(DOTA-FPbG)], caused significantly stronger enhancement in tumors expressing bG (CT26/mbG-eB7) than in tumors not expressing bG (CT26) (p < 0.05). In the magnetic resonance imaging studies using control agent [Gd(DOTA)]
À , the tumors with and without bG expression depicted no significant difference in enhancement on the T1-weighted images. The [Gd(DOTA-FPbG)] also provided significantly more contrast uptake in the CT26/mbG-eB7 tumor than in the normal liver parenchyma, whereas the
Introduction
Several methods have been used to detect and assess hepatic tumors in current clinical practice. These include imaging studies [1, 2] , titration of tumor markers [3, 4] , and histopathology. Imaging methods usually provide a noninvasive in vivo opportunity to detect and to stage tumors. If a lesion does not have inherited tissue contrast, which can be detectable on certain imaging modalities, nonspecific contrast agents are usually needed to contrast the tumor and surrounding normal tissue. Examples are iodinated contrast agents for computed tomography, gadoliniumbased agents for magnetic resonance imaging (MRI), or microbubble agents for ultrasonography. However, from a molecular point of view, most of these methods are only able to detect relatively late-staged, large-sized tumors. To detect and track tumors earlier, researchers are attempting to develop various types of tissue-specific contrast agents for different imaging strategies. These contrast agents can target tumor cells, with the result that the sensitivity and specificity of tumor detection improves [5e8]. To achieve this purpose, a significant amount of the contrast agent should have affinity with tumor cells, and be readily detected by in vivo imaging methods. Certain biomarkers on tumor cells have been identified, and some of these have also been investigated for this particular purpose. One of these specific receptors on tumor cells is b-glucuronidase (bG), an enzyme that exists generally in cell microsomes (endoplasmic reticulum) and lysosomes [9] . Its concentration is low in the human serum and the extracellular substance of normal tissue [10] . However, in previous research, high bG expression on cell membranes of some tumors has been found [11] . Moreover, bG expression can also affect tumor biology, such as metastasis and invasiveness of tumors [11] .
Molecular imaging studies using bG as a biomarker have been done. In former research studies, optical images such as fluorescence or luminescence were used to track subcutaneous tumors of small animals [12] . These experiments have succeeded in detecting tumors as well as monitoring the response to tumor treatments [13] . However, due to limited penetration power, optical image techniques struggle to detect sufficient signals from the deep tissues and organs of large animals or humans. To overcome such limitations, many researchers have attempted to use different imaging technology, such as positron emission tomography (PET) [14] , single-photon emission computed tomography (SPECT) [5, 15, 16] or magnetic resonance imaging (MRI) [17, 18] . PET and SPECT have high sensitivity to detect and locate tumor tissue. They can also provide quantification of signal change, so that lesions may be detected and treatment response monitored. However, use of radioactive agents and relatively poor spatial resolution are disadvantages of nuclear medicine. Synthesis of tissue-or receptor-specific radiopharmaceutical agents is also not widely available in clinical settings. MRI provides excellent spatial resolution without use of ionizing radiation, and has already gained wide clinical application. However, current MRI with use of nonspecific extracellular contrast agents is still limited in sensitivity for detection of diseases down to the molecular level. Improved signal-to-noise ratio of MRI and synthesis of tissue-specific agents are obviously required.
The diagnosis of hepatic tumors, such as hepatocellular carcinoma (HCC), remains a challenge to healthcare systems worldwide, particularly in epidemic areas of chronic viral hepatitis B and C [19, 20] . These malignant tumors are highly fatal. Patients with liver cirrhosis caused by chronic infection of hepatitis B virus, or hepatitis C virus, alcoholism, nonalcoholic steatohepatitis, and aflatoxin injury are at high risk. Early detection of small HCCs with imaging provides the best prognosis. However, current imaging technologies are still not sufficiently sensitive to detect small HCCs. According to a systemic review, regardless of tumor size, sensitivity measures for detecting HCCs with ultrasound, computed tomography (CT), and MRI are 60%, 68%, and 81%, respectively [21] . Sensitivity is even lower for HCCs smaller than 2 cm. According to a study using explanted liver as standard, sensitivity measures for ultrasound, CT, and MRI are only 21%, 40%, and 47%, respectively [22] . More sensitive and specific imaging strategies are undoubtedly highly desirable.
Based on the reasons previously discussed, we used a selfsynthesized MRI contrast agent, ([Gd(DOTA-FPbG)]) (DOTAFPbG Z 1-(2-difluoromethyl-4-(1-(4,7,10-triscarboxymethyl (1,4,7,10-tetraazacyclodecyl))acetamido)phenyl)-b-D-glucopyronuronate) [23] , to perform an in vivo MRI experiment in a murine model of liver tumor. This MRI contrast medium consists of a gadolinium (III) complex and an enzymatic moiety (2-difluoromethylphenyl-b-D-galactopyranose). It can depict significant T1 shortening effect when the tumor has bG expression. The bG enzyme anchored on tumor cell membrane can hydrolyze the contrast medium and remove the b-D-galactopyranose. This molecular process on the cell membrane of the tumor induces contrast enhancement on the T1-weighted MRI. It may produce significant contrast effects between tumors with and without bG, and also between tumors with bG and normal liver tissue.
This study is aimed to provide principal proof of this tracer design. We implanted the colon cancers of the mice that were with and without bG expression separately into different parts of the animal's liver. Both optical images and MRI were performed. To verify the effects of tissuespecific agents that we synthesized, the commercially available nonspecific macrocyclic gadolinium-based agent, [Gd(DOTA)] À , which possesses similar chemical structures, was used as control MRI contrast agent. We compared the results of these imaging scans, and made correlations with histology to evaluate the ability of these imaging technologies in the detection of tumors.
Methods
The culture of tumor cells and animal model setup
Animal experiments were performed in accordance with institute guidelines. The CT26/mbG-eB7 and CT26 murine colon carcinoma cells were cultured at 37 C in an atmosphere of 5% CO 2 incubator. They were grown in Dulbecco's Minimal Essential medium (DMEM) (Sigma, St. Louis, MO, USA) that was supplemented with 5% heat-inactivated bovine calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mM/L glutamine. The culture medium was replaced twice a week. After the cells had grown to occupy approximately 70% of the Petri dish, the cells were collected and stained with trypan blue. The active cells must account for more than 90% of total cells. The concentration of tumor cells was adjusted to 10 7 /mL. Sixto 8-week-old BALB/c mice, each weighing approximately 25e30 g, were purchased from the National Laboratory Animal Center, Taipei, Taiwan. 2 Â 10 6 CT26/mbG-eB7 and 2 Â 10 6 CT26 tumor cells were injected into the subcutaneous tissue of the right and left hind limb, respectively. Two to 3 weeks after the injection, the tumors had grown to a diameter of 10e15 mm, then they were removed surgically and implanted into additional BALB/c mice livers. The BALB/c mice were injected with 90 mg ketamine and 10 mg xylazine per kilogram of body weight into the peritoneal cavity for anesthesia. A 2-cm wound was made on the mice by a midline incision. The CT26/mbG-eB7 and CT26 tumors, each an approximately 1e2 mm diameter clump, were implanted in the right side and left side of the left lateral lobe liver of the BALB/c mice, respectively, and the muscle layers and skin were then sutured. After 7 days, the tumor growth extent of each mouse was confirmed by MRI.
In vivo fluorescence imaging of liver with CT26/mbG-eB7 and CT26 tumors After 10e14 days of tumor implantation, the tumors in the liver had grown up to 5e10 mm in diameter. Each whole body image was obtained by performing a 10-second scan using the IVIS 50 optical imaging system (Caliper Life Sciences, Hopkinton, MA). Mice were anesthetized using 1% isoflurane, and then scanned before and after intravenous injection of fluorescein di-b-D-glucuronide (FDGlcU) (Invitrogen, Eugene, OR) every 5 minutes for 90 minutes. Each mouse was injected with 500 mg FDGlcU from the tail vein. The images were taken to measure the fluorescence signal intensity, and the curve of signal was drawn to analyze the signal changes.
In vivo MRI of liver with CT26/mbG-eB7 and CT26 tumors
Twelve BALB/c mice bearing CT26/mbG-eB7 and CT26 tumors 5e10 mm diameter on the right and left side of the left lateral lobe liver were established. The mice were anesthetized with 90 mg/kg ketamine and 10 mg/kg xylazine. Each mouse was placed in an animal coil in the prone position. MRI was performed using a 3T MRI scanner (Sigma; GE Medical Systems, Milwaukee, WI, USA). T2-weighted coronal fast-spin echo (FSE) (Repetition time (TR)/Echo time (TE) 3000/30 ms) and T1-weighted FSE (TR/TE 100/ 15 ms) axial images before and after intravenous injection of the contrast agent ([Gd(DOTA-FPbG)]) were obtained. After precontrast scanning, six mice were intravenously injected with 0.1 mmol/kg [Gd(DOTA)
Image analysis
The regions of interest from MRI of the tumors, liver tissue, and the water phantom were selected by the researcher. The signal intensity of each tumor and liver were normalized to enhancement ratio by dividing their mean target signal intensity by that of the water phantom (signal to noise ratio, SI/N). The enhancement percentage of the targets was calculated as:
The percentages of SI/N enhancement in different points in time were compared among different groups. The results were expressed as the mean AE standard deviation. The statistics were performed with the software GraphPad Prism (JMP 8, SAS Institute Inc, Cary, NC; Prism, GraphPad software Inc, La Jolla, CA, USA). The two-way analysis of variance using random effect model was used to compare the difference between groups. Post hoc comparison for enhancement at each point of time was also carried out when significant difference occurred. The p values that were below 0.05 were considered statistically significant.
Histologic analysis
After the MRI and fluorescent scanning, the tumors and liver tissues were excised and embedded into a frozen tissue embedding medium (Tissue-Tek, Sakura Finetek, Torrance, CA) in a e80 C refrigerator. Each tumor and liver tissue sample was then sectioned into two 10-mm slices. One section of tissue was stained for bG activity with the bG reporting gene staining kit (Sigma Diagnostics, St. Louis, MO) and counterstained with nuclear fast red. Other tissue sections were stained with a hematoxylin and eosin stain. Each section was examined using upright BX4 microscopy (Olympus, Melville, NY).
Results

In vivo fluorescence imaging of CT26/mbG-eB7 and CT26 tumors
No significant fluorescence signal was found from the images of all time periods selected (Fig. 1) . During the last scan period, we made an incision into the abdomen of a mouse and exposed the liver tissue for a period of 35 minutes after the injection of fluorescent probes FDGlcU ( Fig. 2A) . Then, the image could be detected. There was a green fluorescence of fluorescein isothiocyanate (FITC) on the area of the right side of the liver lobe (Fig. 2B) . The results indicated that the FDGlcU probe was actually hydrolyzed to FITC by bG enzyme in CT26/mbG-eB7 tumor, but fluorescence of FITC in liver tumors could not be detected because of the abdominal muscles and skin barrier.
In vivo MRI of liver with CT26/mbG-eB7 and CT26 tumors As MRI of CT26/mbG-eB7 and the CT26 tumors in liver was performed, scans were performed on mice to obtain coronal section images with T2-weighted sequence. The size and position of tumors could be confirmed from the T2-weighted image. CT26/mbG-eB7 and CT26 tumors encountered similar distributions of contrast medium because they were both implanted in the left lateral lobe of the liver. The separation distance between tumors was more than 5 mm so that tumors would not fuse together (Fig. 3) . The images of tumors and the liver after the intravenous injections of contrast medium [Gd(DOTA-FPbG)] showed stronger signal intensity in the area of the CT26/mbG-eB7 tumor within a period of 5 minutes. The signal enhancement was not present in the area of the CT26 tumor. The signals of CT26/mbG-eB7 tumors were higher than those of CT26 tumors 10 minutes after the injection of contrast agent (Fig. 4) , and the appearance of enhancement remained until it reached 90 minutes. The highest signal in the average curve of CT26/mbG-eB7 tumors was observed 10 minutes after injection. It showed 25% enhancement more than the average signal of the CT26 tumors, and 20% more than an average signal of liver tissues (Fig. 5) . The signals obtained from CT26/mbG-eB7 and CT26 tumors were significantly different (p < 0.05). . The apparent signal enhancement in the liver tissue was observed, but the signal intensities of CT26/mbG-eB7 and the CT26 tumors were inferior to those of the liver tissues (Fig. 6) . The average signals of CT26/mbG-eB7 and CT26 tumors showed similar fluctuations along with time (Fig. 7) . The signals obtained from CT26/mbG-eB7 and CT26 tumors were not significantly different (p > 0.05).
Histologic analysis and immune stain of tumors
To confirm the correlation between images and histologic analysis, BALB/c mice were sacrificed by excessive anesthesia, and the liver and tumors after MRI were excised. These tissues were embedded in the frozen tissue embedding medium and sectored into two 10-mm slices. The slices were stained with X-GlcA dyes: a bG reporting gene staining kit, and hematoxylin and eosin stain, respectively. Then, we compared the MRI scans and tissue sections. As shown in Fig. 8 , the slice showed CT26/mbG-eB7 tumor and liver tissues that were stained by hematoxylin and eosin (A and C), and stained by X-GlcA (B and D). The area of CT26/mbGeB7 tumor was dyed with blue color because of the presence of bG enzyme in the tumor. The CT26 tumor and liver tissue were not stained blue due to the absence of bG enzyme in those tissues. The results of histology and MRI were consistent with the effects of the bG enzyme.
Discussion
In this study, we confirmed that the MRI contrast medium [Gd(DOTA-FPbG)] could depict tumors with bG expression in liver of a mouse model. This contrast medium is designed to target the bG of the tumor cells. The highly expressive bG enzyme of the tumor cells hydrolyzes the contrast medium and expresses a T 1 shortening effect. At the same time, the concentration on the tumor cell is also high enough to be detected by current MRI. In addition, we have also documented that this imaging strategy can not only detect tumors, but also differentiate tumors with and without certain biomarkers in a deep visceral organ in vivo by a noninvasive imaging modality, i.e., MRI, which has already been available in most current clinical settings.
In the fluorescence imaging experiment, the in vivo optical imaging system is unable to detect liver tumors have the [Gd(DOTA)] À chelate with ring structure. The difference between the two contrast media is that [Gd(DOTAFPbG)] has the functional structure of glucuronide base to be hydrolyzed by bG enzyme of the tumor, whereas [Gd(DOTA)] À does not. As the glucuronide base is removed from [Gd(DOTAFPbG)], the surplus part of the agent binds with bG or the albumin and remains in the tumor tissue for a longer time period. An inference can be confirmed from the timeenhancement graph in the signal of tumors in the liver with these two contrast media. Our results showed that the distribution and the enhancement of extracellular contrast medium in the liver tissues and CT26/mbG-eB7, and CT26 tumors are not statistically different. This also indicates that the extracellular space and vascular distribution of CT26/ mbG-eB7 and the CT26 tumors are similar [24] . A different result for CT26/mbG-eB7 and the CT26 tumor images with contrast agent [Gd(DOTA-FPbG)] due to perfusion and extracellular environments is therefore unlikely.
The average signal intensity of liver tissues in the MRI scan with [Gd(DOTA-FPbG)] and [Gd(DOTA)]
À is higher than the signal intensity of CT26 tumors 5 minutes after injection, and then it decreases rapidly. The fast-increasing and decaying trend of signal strength of the liver is due to high blood perfusion in the liver tissues. The contrast media in the serum are excreted rapidly by the kidney. The liver tissues remain with just a small amount of contrast media in extracellular spaces. The signal intensity of liver reduces quickly and becomes ever closer to the signal intensity of CT26 tumors.
MRI can be performed successfully in large animals and humans without limitation of penetration in optical imaging. It also shows the images with better spatial resolution than those from modalities of nuclear medicine. There are limitations to the approach we used in the study. The bG enzyme does not exist in all membranes of tumor cells. Some researchers point out that bG was one of the often-expressed biomarkers on many tumor membranes. The contrast medium [Gd(DOTA-FPbG)] can be applied to detect whether the tumor expresses bG enzyme. Many oncologic studies try to detect special biomarkers and administer chemotherapy with tumor-specific or sensitive prodrugs for tumor treatment [35] . These prodrugs may have a high affinity with tumors and may be activated by the enzyme in tumor cells. Due to its better tumor affinity, the dosage and toxicity of patients can be reduced without compromising the treatment effect. Molecular imaging, such as our design in this experiment, may also play a role in management of oncologic patients in the future.
In conclusion, we confirm that better contrast enhancement can be readily detected in vivo by use of a tissue-specific MRI contrast agent targeting tumor cells with specific biomarkers in a clinical MRI scanner. Molecular imaging strategy can expand to a more clinically feasible imaging modality as long as tissue-specific contrast agents can be successfully synthesized and safely administered.
